Covid-19 Vaccine mRNA

  • TRADE NAME: Comirnaty (Pfizer-BioNTech)
  • INDICATIONS: Prevention of coronavirus disease 2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • SYNONYM: Tozinameran; Covid-19 mRNA Vaccine BNT162b2
  • CLASS: Covid-19 Vaccine, Vaccine

FDA APPROVAL DATE: 08/23/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
Insufficient data to inform of vaccine-associated risks in pregnancy.

Increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The Centers for Disease Control and Prevention (CDC) have published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis.

Our database has 10 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CENTRAL NERVOUS SYSTEM.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OTHER.


Page last updated 09/16/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top